Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSKVX000000048110
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSKVX000000048110 is an investigational influenza vaccine developed by GSK (GlaxoSmithKline Biologicals). It is designed to provide protection against seasonal influenza. The vaccine is typically evaluated in clinical trials to assess its safety, reactogenicity, and immunogenicity in various populations, including healthy adults. As a vaccine, its primary mechanism of action involves the induction of an immune response, specifically the production of antibodies against the hemagglutinin protein of the influenza virus, which prevents the virus from entering host cells and causing infection.
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on GSKVX000000048110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSKVX000000048110.